Core Insights - SOPHiA GENETICS S.A. reported a strong Q3 performance with a 23% year-over-year revenue growth, driven by new customer signings and expansion within existing accounts [4][27][40] - The company raised its 2025 revenue guidance to a range of $75 million to $77 million, reflecting confidence in continued growth momentum [3][36] Customer Growth and Expansion - In Q3, SOPHiA signed 31 new customers, bringing the total for 2025 to 94, surpassing the previous year's total of 92 [3][17] - The company successfully expanded its offerings at existing institutions, including major deals with Gustave Roussy and New South Wales Pathology [2][5] Market Performance - U.S. revenue grew by 30% year-over-year, contributing significantly to overall growth [1][15] - EMEA region saw a 24% revenue growth, with notable contributions from the UK and Belgium, which grew by 120% and 70% respectively [14][15] Product Development and Innovation - The company highlighted the success of its liquid biopsy application, MSK Access, which is gaining traction among customers [5][7] - SOPHiA introduced a new technology called SOPHiA DDM Digital Twins, aimed at enhancing treatment decision-making for oncologists [9][10] Financial Performance - Total revenue for Q3 was $19.5 million, compared to $15.9 million in the same quarter last year, with gross profit increasing to $12.9 million [27][29] - Adjusted gross margin remained strong at 73.1%, despite a significant increase in data processed by the platform [11][29] Strategic Partnerships - The partnership with AstraZeneca is expected to enhance market access for liquid biopsy testing and contribute to drug development [7][21] - Collaborations with Myriad Genetics and ADAM Innovations are aimed at developing regulated companion diagnostics in the U.S. and Japan [7][21][63] Future Outlook - The company anticipates continued growth in 2026, driven by strong customer demand and the successful implementation of new applications [36][70] - SOPHiA is focused on optimizing costs while expanding its customer base and product offerings [12][38]

Welcome everyone. Welcome to GTC. My name is Jason Fenwick.Uh I'm on the genomics and healthcare team here at NVIDIA. And today I'll be the the host for the session. Our speaker for today is Yurgi Camlong.He is pioneering the global datadriven medicine movement. Founded co-founded Sophia Genetics in 2011. is a member of the advisory council on digital transformation for for the Swiss government and was recognized by EY as emergent entrepreneur of the year.A molecular biologist with a PhD and EMBA. He has be ...

Core Insights - SOPHiA GENETICS has expanded its partnership with AstraZeneca to enhance data-driven medicine for breast cancer treatment [1][3] - The collaboration will utilize SOPHiA GENETICS's AI Factories to analyze multimodal healthcare data and generate insights for optimizing treatment outcomes [2][3] Company Overview - SOPHiA GENETICS is a cloud-native healthcare technology company focused on data-driven medicine, particularly in cancer and rare disorders [5] - The company offers the SOPHiA DDM™ Platform, which analyzes complex genomic and multimodal data to provide actionable insights [5] Partnership Details - The multi-year collaboration aims to develop a bespoke AI-powered predictive model for breast cancer treatment [1][2] - AstraZeneca will leverage SOPHiA GENETICS's AI capabilities to generate real-world evidence and enhance clinical decision-making [2][3] Strategic Importance - This partnership highlights the increasing demand for secure and scalable AI applications in healthcare [3] - The collaboration reinforces SOPHiA GENETICS' position as a trusted technology partner in advancing global health through federated data analytics [3]

Group 1 - SOPHiA GENETICS will release its financial results for Q2 2025 on August 5, 2025, before U.S. markets open [1] - A conference call to discuss the financial results and business outlook will take place at 8:00 a.m. EDT [1] - The call will be webcast live on the SOPHiA GENETICS Investor Relations Website, with a replay available afterward [2] Group 2 - SOPHiA GENETICS is a cloud-native software company focused on data-driven medicine, particularly in cancer and rare disorders [3] - The company developed the SOPHiA DDM™ Platform, which analyzes complex multimodal data to provide actionable insights [3] - SOPHiA GENETICS aims to expand access to data-driven medicine globally through the use of AI [3]

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was $17.8 million, up from $15.8 million in Q1 2024, representing a year-over-year growth of 13% [31] - On a constant currency basis, revenue growth was 15%, with foreign exchange headwinds negatively impacting reported revenue by approximately $0.4 million [31] - Adjusted EBITDA loss improved by 24% year-over-year to $9.8 million in Q1 2025 [35] - Adjusted gross margin reached a record high of 75.7%, up from 70.6% in Q1 2024 [33] Business Line Data and Key Metrics Changes - Core genomic customers increased to 490 as of March 31, 2025, up from 463 in the prior year [31] - The company implemented 33 new customers in Q1 2025, compared to an average of 23 per quarter in 2024 [8][47] - Hematology-oncology (HemOnc) volumes grew 34% year-over-year in Q1 2025, with over 180 HemOnc customers globally [20] Market Data and Key Metrics Changes - Revenue and analysis volume from U.S. core genomic customers grew over 30% year-over-year [9] - UK analysis volume grew over 60% year-over-year, with UK revenue up approximately 80% [19] - In Asia Pacific, North America and Asia Pacific outperformed with 3240% year-over-year volume growth [18] Company Strategy and Development Direction - The company aims to capitalize on new customer signings by expediting implementation times and expanding across those accounts [8] - Focus areas for growth in 2025 include the U.S. market, new applications like MSK Access and MSK Impact, and partnerships with biopharma [10][11] - The company is positioned to leverage its scalable cloud-based platform to support medical innovations and expand its offerings in liquid biopsy and solid tumor applications [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term growth potential, citing a strong start to 2025 and a solid pipeline of new business [43] - The company reaffirmed its full-year revenue guidance for 2025 of $70 million to $76 million, representing 10% to 17% growth [37] - Management noted that while Q1 results were strong, they expect the year to be back half weighted due to new business coming online [37][93] Other Important Information - The company finished Q1 2025 with cash and cash equivalents of approximately $68.5 million, with access to an additional $35 million through a financing line [36][88] - Total cash burn improved to $11.7 million in Q1 2025, down from $19.5 million in the prior year [36] Q&A Session Summary Question: Actions taken to accelerate implementation times - Management highlighted that they implemented 33 new customers in Q1 2025, up from an average of 23 in 2024, due to scaling up team capabilities and creating tooling and automation to speed up processes [47][49] Question: Average contract value increase and enterprise sales - Management confirmed that 58% of customers are using two or more applications, indicating room for expansion. The increase in average contract value is attributed to more complex solutions and enterprise-level sales [53][55] Question: Sustainability of gross margins above 75% - Management acknowledged that while Q1 gross margins were higher than expected due to a favorable mix, they anticipate continued year-over-year improvement but not at the same level in subsequent quarters [62][63] Question: Biopharma side opportunities and guidance - Management indicated that while they expect the biopharma segment to be flat in 2025, they are seeing good momentum and opportunities in the pipeline, particularly in companion diagnostics [68] Question: Impact of macro environment on capital investments - Management noted that while there is a trend of constraints on capital investments, their model operates on an OpEx basis, which may present opportunities for growth as labs seek to avoid large capital expenditures [71][73]

Company Overview - SOPHiA GENETICS is a cloud-native software company focused on data-driven medicine, utilizing AI to enhance patient care for cancer and rare disorders globally [3]. - The company has developed the SOPHiA DDM™ Platform, which analyzes complex multimodal data, including genomics, radiomics, clinical, biological, and digital pathology data, to provide real-time actionable insights [3]. Financial Results Announcement - SOPHiA GENETICS will release its financial results for the first quarter of 2025 before U.S. markets open on May 6, 2025 [1]. - A conference call to discuss the financial results and business outlook will take place at 8:00 a.m. EDT / 2:00 p.m. CET on the same day [1]. Investor Relations - The conference call will be available via a live webcast on the SOPHiA GENETICS Investor Relations Website, with a replay accessible after the event [2].